CIMA LABS Announces License And Supply Agreement With Wyeth Consumer Healthcare.Business Editors & Health/Medical Writers CIMA LABS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq:CIMA) announced today it has signed a license and supply agreement with Wyeth Consumer Healthcare for a DuraSolv(R) loratadine over-the-counter version of Claritin(R) RediTabs(R). Under this agreement, CIMA will work with Wyeth Consumer Healthcare to complete the development and registration process, and will provide commercial supplies of DuraSolv loratadine. Wyeth Consumer Healthcare is a division of Wyeth (NYSE NYSE See: New York Stock Exchange :WYE). John M. Siebert, Ph.D., CIMA's President and Chief Executive Officer, commented: "This relationship developed as a result of the positive interaction CIMA had with Wyeth's former generic drug generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. division. We expect DuraSolv loratadine to become a strong component of future revenues for both Wyeth Consumer Healthcare and CIMA." About CIMA: CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(R). Based on our technologies, an active drug ingredient is formulated into a new, orally disintegrating dosage form A dosage form is the physical form of a dose of medication, such as a capsule or injection. The route of administration is dependent on the dosage form of a given drug. that dissolves quickly in the mouth without chewing chewing or mastication Up-and-down and side-to-side movements of the lower jaw, using the teeth to grind food for easier swallowing. During chewing, the tongue shapes food into a lump and saliva lubricates it for swallowing. or the need for water. CIMA's business involves a dual operating strategy. We develop and manufacture fast-dissolve versions of active drug ingredients for pharmaceutical company partners for whom we currently produce three branded prescription pharmaceuticals and two over-the-counter brands. In an expansion of its portfolio of partner-funded collaborations, CIMA recently entered into a product development, license and supply agreement with Schering-Plough Limited, a subsidiary of Schering-Plough Corporation for a prescription product that will utilize CIMA's OraSolv fast-dissolve drug delivery system. CIMA is also developing proprietary products that will utilize our OraSolv and DuraSolv technologies, as well as our new OraVescent(R) enhanced absorption, transmucosal drug delivery system. About Wyeth Consumer Heathcare: Wyeth Consumer Healthcare, a division of Wyeth, is one of the world's leaders in the development, manufacture and marketing of non-prescription medicines, vitamins and nutritional products, including such established brands as Advil(R), Centrum centrum /cen·trum/ (sen´trum) pl. cen´tra [L.] 1. a center. 2. the body of a vertebra. cen·trum n. pl. cen·trums or cen·tra 1. (R), Chap Stick Chap Stick A trademark used for a medicinal preparation for the prevention or treatment of chapped lips. (R), Dimetapp(R) and Robitussin(R). About Wyeth: Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Fort Dodge, city (1990 pop. 25,894), seat of Webster co., central Iowa, on the Des Moines River; settled c.1846; inc. 1869. Fort Clarke was built on the site in 1850 and renamed Fort Dodge the following year. Animal Health. Cautionary Statement: This press release, including the information related to CIMA's expectations about new product introductions, marketing efforts of third parties, sources of future revenues, earnings and revenues, contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. A number of factors could cause actual results to differ materially from CIMA's assumptions and expectations. These factors include the timely and successful completion of product development activities, regulatory approval for proposed products, consumer acceptance of CIMA's products and the success of pharmaceutical companies in marketing CIMA's products. Additional factors that may cause actual results to differ from CIMA's assumptions and expectations include those set forth under the heading "Factors That Could Affect Future Results" included in CIMA's most recent filings with the Securities and Exchange Commission. All forward-looking statements are qualified by, and should be considered in conjunction with, such cautionary statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion